Abstract 174: Public Health Potential of Improved Reperfusion in Thrombectomy for Stroke Based on HERMES Collaboration Data

Abstract

Introduction: The benefit that endovascular thrombectomy (EVT) offers to stroke patients with large vessel occlusions depends strongly on reperfusion grade as defined by the mTICI (modified Thrombolysis in Cerebral Infarction) scale. Our aim was to estimate the public health potential of improved reperfusion. Methods: A Markov model estimated lifetime quality-adjusted life years (QALY) of EVT-treated patients and associated costs based on mTICI grades. The analysis was performed from a United States healthcare perspective. Input parameters were based on best available evidence, including patient data from the HERMES collaboration. The lead analysis was conducted for stroke onset at 65 years. Overall lifetime costs and the net monetary benefit (NMB), which combines weighted QALYs and costs into one composite outcome, were analyzed. A willingness-to-pay threshold of $100,000 per QALY was used for NMB calculations. Results: Lifetime QALYs and the NMB per patient increased for every grade of improved mTICI reperfusion (Fig 1). The final mTICI 2C/3 rate across all trials in the HERMES collaboration was 31%, yielding on average 5.09 QALYs at lifetime costs of $230,799, resulting in a positive NMB of $278,336. Every 10% increase in the final mTICI 2C/3 rate would yield 0.16 incremental QALYs and $16,878 incremental NMB for the average patient. For a national 10% improvement of the mTICI 2C/3 rate of all EVT-treated patients in the United States, we estimated 3,645 additional QALYs and an incremental NMB of $385 million per year. Conclusions: The public health and economic impact of the grade of reperfusion is significant, warranting further improvement of devices and procedural techniques.